Emerging data suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to provide a significant development for obesity management . Early clinical https://bookmark-master.com/story21478102/a-retatrutide-substance-the-breakthrough-in-weight-management